TY - JOUR T1 - Bacterial genotypic and patient risk factors for adverse outcomes in <em>Escherichia coli</em> bloodstream infections: a prospective molecular-epidemiological study JF - medRxiv DO - 10.1101/2021.06.18.21258557 SP - 2021.06.18.21258557 AU - Elita Jauneikaite AU - Kate Honeyford AU - Oliver Blandy AU - Mia Mosavie AU - Max Pearson AU - Farzan A. Ramzan AU - Matthew J. Ellington AU - Julian Parkhill AU - Céire E Costelloe AU - Neil Woodford AU - Shiranee Sriskandan Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/18/2021.06.18.21258557.abstract N2 - Background Escherichia coli bloodstream infections have increased rapidly in the UK, for reasons that are unclear. The relevance of highly fit, or multi-drug resistant lineages such as ST131 to overall E. coli disease burden remains to be fully determined. We set out to characterise the prevalence of E. coli multi-locus sequence types (MLST) and determine if these were associated with adverse outcomes in an urban population of E. coli bacteraemia patients.Methods We undertook whole genome sequencing of E. coli blood isolates from all patients with diagnosed E. coli bacteraemia in north-west London from July 2015 to August 2016 and assigned multi-locus sequence types to all isolates. Isolate sequence types were linked to routinely collected antimicrobial susceptibility, patient demographic, and clinical outcome data to explore relationships between the E. coli sequence types, patient factors, and outcomes.Findings A total of 551 E. coli genomes were available for analysis. More than half of these cases were caused by four E. coli sequence types: ST131 (21%), ST73 (15%), ST69 (9%) and ST95 (8%). E. coli genotype ST131-C2 was associated with non-susceptibility to quinolones and third-generation cephalosporins, and also to amoxicillin, augmentin, gentamicin and trimethoprim. An association between the ST131-C2 lineage and longer length-of-stay was detected, although multivariable regression modelling did not demonstrate an association between E. coli sequence type and mortality. However, a number of unexpected associations were identified, including gentamicin non-susceptibility, ethnicity, and sex that might influence mortality and length-of-stay, requiring further research.Interpretation Although E. coli sequence type was associated with antimicrobial non-susceptibility patterns and length-of-stay, we did not find that E. coli sequence type was associated with increased mortality. Where ST131 is prevalent, caution is required when pairing beta-lactam agents with gentamicin or using single agent aminoglycosides.Funding UK NIHR HPRU, Wellcome Trust, Rosetrees Trust, Stoneygate Trust.Evidence before this study E. coli is the leading cause of bacteraemia in adults, with consequent major impact on patient morbidity and mortality, as well as cost of care. Identification of microbial and patient factors that contribute to severity from E. coli bacteraemia could inform clinical guidelines and improve outcomes. We searched PubMed for articles published in English between 1st of Jan 1999 to 3rd of May 2021 using the following terms: (“Escherichia coli” OR “E. coli”) AND (“bacteraemia” OR “bloodstream infection”) AND (“genotype” OR “multi-locus sequence typing” OR “MLST”). We screened titles, abstracts, and bibliographies of relevant articles to identify reports that examine microbial factors that influence outcome. Previous studies have examined the association between a narrow range of E. coli lineages carrying specific antimicrobial resistance genes and prior antibiotic consumption, patient comorbidities, and mortality. Only two previous studies have examined the association of a wider range of E. coli sequence types (via MLST or whole genome sequencing) with clinical disease phenotype. We provide an integrated observational analysis of E. coli sequence types, patient demographic data, and disease outcomes.Added value of this study We provide whole genome sequences from an un-biased collection of 551 E. coli strains causing consecutive bloodstream infections (BSI) in a one-year period in London. The study confirms ST131 to be the single leading BSI-causing genotype, albeit accounting for just 21% of infections. Only half of these were from the so-called multi-drug resistant ST131-C2 lineage however, suggesting factors other than antimicrobial resistance alone contribute to fitness of ST131, and other currently dominant lineages. The study provides a valuable resource to link genome sequence to antimicrobial resistance phenotypes and evaluates the contribution of both bacterial sequence type and patient factors to disease outcome. E. coli ST131 subclade C2 was associated with non-susceptibility to multiple antibiotics as well as a longer length-of-stay, underlining a value in sequence-type surveillance, but we did not detect an association with mortality. Multi-variate analysis unexpectedly identified ethnicity as a potential contributor to 90-day mortality, mandating further investigation, while microbial gentamicin resistance was also linked to adverse outcome.Implications of all available evidence E. coli bloodstream infections continue to rise in the UK, despite implemented strategies aimed at reducing E. coli invasive infections and antimicrobial resistance. Certain E. coli lineages are more likely to be multidrug-resistant or associated with specific infection types, however a more detailed understanding of changes in these pathogenic lineages over time in vulnerable populations is needed. Although multi-drug resistant lineages such as ST131-C2 contribute to prolonged length-of-stay, factors other than E. coli genotype may have a greater role to play in final outcome. While co-morbidities play a major role in mortality from E. coli bacteraemia, other demographic factors require attention. A more comprehensive analysis of associations between E. coli genotype, patient factors, antimicrobial resistance phenotypes and clinical outcomes could inform prescribing guidelines for both urinary tract and invasive E. coli infections. Such information will further serve as a potential driver for developing and implementing lineage-specific E. coli vaccines in the future.Competing Interest StatementJP is a paid consultant to Next Gen Diagnostics Llc. MJE and NW are members of PHEs Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, which has received financial support for conference attendance, lectures, research projects, or contracted evaluations from numerous sources, including Accelerate Diagnostics, Achaogen Inc, Allecra Therapeutics, Amplex, AstraZeneca UK Ltd, AusDiagnostics, Basilea Pharmaceutica, Becton Dickinson Diagnostics, bioMerieux, Bio-Rad Laboratories, British Society for Antimicrobial Chemotherapy, Cepheid, Check-Points B.V., Cubist Pharmaceuticals, Department of Health, Enigma Diagnostics, the European Centre for Disease Prevention and Control, Food Standards Agency, GenePOC, GlaxoSmithKline Services Ltd, Helperby Therapeutics, Henry Stewart Talks, International Health Management Associates Ltd, Innovate UK, Kalidex Pharmaceuticals, Melinta Therapeutics, Merck Sharpe and Dohme, Meiji Seika Pharma Co Ltd, Mobidiag, Momentum Biosciences Ltd, Neem Biotech, NIHR, Nordic Pharma Ltd, Norgine Pharmaceuticals, Paratek, Rabiotics Rx, Rempex Pharmaceuticals Ltd, Roche, Rokitan Ltd, Smith and Nephew UK Ltd, Shionogi and Co Ltd, Tetraphase Pharmaceuticals, Trius Therapeutics, VenatoRx Pharmaceuticals, Wockhardt Ltd, and the World Health Organization. All other authors have no competing interest to declare.Funding StatementThe research was funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Imperial College London in partnership with Public Health England (HPRU-2012-10047). This report is independent research funded by the National Institute for Health Research. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health and Social Care or Public Health England. NW and MJE were also supported by PHE and the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) and the Medical Research Council (MRC) as part of the ST131TS Consortium under grant code MR/R002843/1. The funding sources had no role in study design, data collection, analysis, or decision to submit the manuscript for publication. SS acknowledges the support of the NIHR Imperial Biomedical Research Centre (BRC). EJ is a Rosetrees/Stoneygate 2017 Imperial College Research Fellow (M683). CEC is supported by a personal NIHR Career Development Fellowship (NIHR-2016-090-015). Imperial College London is grateful for the support from the North West London NIHR Applied Research Collaboration. The funders had no role in study design or writing.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The collection of microbial isolates and linkage to routinely obtained healthcare data prior to anonymisation was approved by an NHS Research Ethics Committee (West London Research Ethics Committee, formerly Hammersmith and Queen Charlotte’s &amp; Chelsea Research Ethics Committee). Ethics approval reference number 06/Q0406/20.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWhole genome sequencing reads were deposited in European Nucleotide Archive under the BioProject accession PRJEB20357, individual isolate accession numbers are shown in Table S5. ER -